-
ALSO READ
'Pharma may see recovery with FY19 profit set to jump 20-22%' India pharma exports to touch $20 bln by 2020: study J B Chemicals & Pharmaceuticals receives EU cGMP approval for facility at Panoli Sun Pharma gains after settling patent litigation for generic Centaur Pharmaceuticals & Kibow Biotech, USA, announce a Strategic Alliance to Market Renadyl in India for Chronic Kidney Disease -
Glenmark Pharmaceuticals and Helsinn Group (Helsinn), a Swiss pharmaceutical group focused on building quality cancer care products, have entered into an exclusive licensing agreement to introduce AKYNZEO in India and Nepal.
AKYNZEO, an oral fixed combination of netupitant 300mg and palonosetron 0.5mg in capsule form, is used for prevention of chemotherapy-induced nausea and vomiting (CINV).
The licensing agreement with Glenmark for AKYNZEO represents Helsinn's first such agreement in India. Glenmark will have exclusive marketing rights for AKYNZEO in India and Nepal.
Glenmark has received marketing approval for AKYNZEO from the Central Drugs Standard Control Organization (CDSCO).
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
RECOMMENDED FOR YOU